FDA Approves Telix's Brain Cancer Imaging Drug Pixclara for Glioma

The U.S. Food and Drug Administration (FDA) has approved Telix's New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer). This approval addresses a significant unmet need by helping physicians differentiate recurrent or progressive glioma from treatment-related changes in both adult and pediatric patients.